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Abstract
Objectives The aim was to evaluate the activity of seven
medicinal, anti-inflammatory plants at the hH4R with focus
on defined chemical compounds from Curcuma longa.
Materials Activities were analyzed with membrane
preparations from Sf9 cells, transiently expressing the
hH4R, Gai2 and Gb1c2 subunits.
Methods From the methanolic extract of C. longa cur-
cumin (1), demethoxycurcumin (2) and bis(4-hydroxy-
cinnamoyl)methane (3) were isolated, purified with HPLC
(elution-time 10.20, 9.66, 9.20 min, respectively) and
together with six additional extracts, were characterized via
radioligand binding studies at the hH4R.
Results Compounds from C. longa were the most potent
ligands at the hH4R. They exhibited estimated Ki values of
4.26–6.26 lM (1.57–2.31 lg/mL) (1); 6.66––8.97 lM
(2.26–3.04 lg/mL) (2) and 10.24–14.57 lM (3.16–4.49 lg/
mL) (3) (95%CI). The estimatedKi value of the crude extract
of curcumawas 0.50–0.81 lg/mL.Fractionated curcumin and
the crude extract surpassed the effect of pure curcumin with a
Ki value of 5.54 lMor 2.04 lg/mL [95%CI (4.47–6.86 lM),
(1.65–2.53 lg/mL)].
Conclusion Within this study, defined compounds of C.
longa were recognized as potential ligands and reasonable
lead structures at the hH4R. The mode of anti-inflammatory
action of curcumin was further elucidated and the role of
extracts in traditional phytomedicine was strengthened.
Keywords Curcuma longa  Natural compounds 
hH4R  Inflammatory diseases  Phenylpropanoids
Introduction
The evaluation of the fourth human histamine receptor
subtype (hH4R) revealed its crucial role in chemotaxis,
inflammation and autoimmune disorders [1]. Drug research
on the hH4R is highly interested in antagonists, due to their
suggested potential in the treatment of inflammatory dis-
eases [2].
Natural products have been a source for therapeutic
agents for ages [3] and a high amount of currently used
biologically active agents are natural product inspired
compounds or their derivatives [4]. They are a well-studied
source for pharmaceutical development and provide high
hit rates in pharmacological screenings as lead-compounds
[5]. Therefore, drug discovery and development are highly
interested in novel drugs and bioactive lead-compounds out
of nature’s kitchen [6]. Plants and spices like curcuma,
thyme, saffron, cumin, and ephedra species are well
reported for their use in traditional medicine, especially
against inflammatory events [7–11] and could meet the
demands for drug development by supporting natural-based
compounds for treating inflammatory diseases. A well
investigated representative of these plants is Curcuma
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longa L., a perennial herb of the Zingiberaceae (ginger)
family [12]. It has traditionally been used to treat various
conditions [13] and extensive research in vitro and in vivo
during the last few decades revealed that C. longa pos-
sesses anti-inflammatory effects [14]. Its inhibition of NF-
jB (nuclear factor ‘kappa-light-chain-enhancer’ of acti-
vated B-cells), Akt-phosphorylation (protein kinase B),
m-TOR activation (mechanistic target of rapamycin) and in
contrast an activation of AMPK (50 AMP-activated protein
kinase) in inflammatory events are well reported, but its
mode of action is still not conclusively investigated [15].
The aim of the current study is to evaluate the activity of
different plant extracts from traditional phytomedicine
approaches at the hH4R with a focus on defined chemical
structures from C. longa. All seven plants were investi-
gated because of their traditional use against inflammatory
events and could support the treatment of those. Especially
curcuma’s purified and isolated compounds display dif-
ferent structural features from any previously known
ligands and may provide new directions for selective and
specific scaffolds for the hH4R, opening new ways in
treating inflammatory diseases. In doing so the anti-in-
flammatory mode of action of curcuma can be further
elucidated, supporting its rational use in the adjuvant
treatment of inflammatory diseases.
Materials and methods
Curcuma longa L. for the first extract was purchased from
Al Alim-Medicinal Herb Center (Zippori, Israel), all other
herbs and C. longa for the repeated measurement were
gathered by the Institute of the Qasemi Research Centre
(Baka EL-Garbya, Israel). Pure curcumin was kindly pro-
vided by Prof. Dr. Gunter Eckert, Frankfurt/Germany,
another batch as curcumin 2 was purchased from Sigma
Aldrich.
Plant extract preparation
Each extract stems from one plant sample, except for C.
longa, that was extracted from two different samples. The
respective plant parts were chosen, because of their most
common use in traditional phytomedicine. 20 mL of
methanol were added to 2 g of the dried plant material.
Samples were sonicated for 120 min at 45 C and left for
2 h. The liquid was made to pass through a 0.4 lm filter
and concentrated by a rotary vacuum evaporator.
HPLC experiments
The analytical HPLC (High performance liquid chro-
matography) was a Waters Alliance (e2695 separations
module) with a 2998 Photodiode Array detector (PDA).
The preparative HPLC system consisted of a 3535 qua-
ternary gradient module with a 996 PDA detector. The
analytical experiments were run on an ODS column of
Waters (XBridge, 4.6 ID 9 150 mm, 5 lm, guard column
of Xbridge ODS, 20 mm 9 4.6 mm ID, 5 lm). The
mobile phase consisted of acidified water at pH 3 adjusted
with phosphoric acid (A) and acetonitrile (B). Linear
gradient started at 55% of (A) and 45% of (B) to reach
30% (A) and 70% (B) in 13 min then to 100% (B) in
1 min keeping it at 100% (B) for 5 min and back to 55%
(A) in 1 min. PDA wavelengths ranged from 200 to
600 nm. The flow rate was set to 1 mL/min, the injection
volume was 10 lL and the column temperature was at
room temperature. The three major fractions were rein-
jected to the prep-HPLC with an ODS column (Agilent
PrepHT C18, 22.2 9 250 mm, 10 lm). The elution pro-
gram was set as in the analytical mode, the flow rate was
20 mL/min and 1 mL injection volume. Fractionation of
the methanolic crude extract of C. longa by preparative
HPLC lead to isolation of three purified compounds (1, 2,
3) (purity[90%). The isolated compounds were further
determined by HR-ESI–MS (High-resolution electrospray
ionization mass spectrometry) in positive mode (LTQ-
Orbitrap XL hybrid ion trap with a high resolution
Orbitrap detection system, Thermo Scientific, USA).
Membrane preparation
Cell culture and membrane preparation were performed
according to Schneider and Seifert [16] to gain membrane
preparations from Sf9 cells transiently expressing the
hH4R, the Gai2 and Gb1c2 subunits. Briefly, Sf9 cells were
cultured in spinner flasks at 28 C and 100 rpm in Sf9
medium [with 5% (v/v) fetal bovine serum and 10 lL/mL
penicillin/streptomycin]. 3 9 106 cells/mL was infected
with a baculovirus solution (1:100), containing the human
histamine H4 receptor and the Gai2 and Gb1c2 subunits.
48 h after infection cells were harvested and membrane
preparation was performed at 4 C. The infected Sf9 cells
were centrifuged at 1000 rpm for 10 min. The resulting
pellet was resuspended in phosphate buffered saline
(PBS) and centrifuged again at 1000 rpm for 10 min.
Afterwards the pellet was resuspended in 15 mL lysis
buffer [80 lM benzamidine, 20 lM leupeptin,
200 lM phenylmethyl sulfonylfluoride (PMSF), in H4
binding buffer (13 mM MgCl2, 1 mM EDTA and 75 mM
Tris/HCl, pH 7.4)] per 100 mL cell suspension. After
homogenization in a hand potter the suspension was
centrifuged at 500 rpm for 5 min and the supernatant was
centrifuged for 20 min at 18,000 rpm. The resulting pellet
was resuspended in lysis buffer, homogenized and cen-
trifuged for 20 min at 18,000 rpm. The pellet was
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resuspended in 12 mL H4 binding buffer per 100 mL cell
suspension, homogenized and stored as 1 mL aliquots at
-70 C.
[3H]Histamine competition binding assay
The assays were performed as published recently [17].
The extracts (A)–(F) were tested at fixed concentrations
of 5 lg/mL in two independent experiments to allow a
rough screening. The crude extract of curcuma and its
three isolated compounds were tested at 10 lg/mL in
three independent experiments, performed in triplicates
for one-point measurements. For concentration–response
curves, the curcuma extract and compounds (2)–(3) were
tested at four concentrations ranging from 0.3 to 10 lg/
mL allowing an estimation of the 95% confidence inter-
vals of the Ki values. Compound (1) and pure curcumin
were tested at six and eight distinct concentrations,
respectively (0.01 ng/mL–100 lg/mL). A second crude
extract of curcuma was tested at eleven concentrations
(0.01 ng/mL–100 lg/mL) and the testing of pure cur-
cumin (curcumin 2) was repeated in ten concentrations
(0.01–10 ng/mL), allowing determination of the Ki values
for the latter four substances. The used concentrations
were chosen as standard logarithmic or half-logarithmic
concentrations, limited by the solubility of the given
compounds in the assay buffer. Bound radioligand was
separated from free radioligand by filtration with a cell
harvester (Inotech, Brandon, FL). The amount of bound
radioactive ligand collected on the filtermats was deter-
mined by liquid scintillation counting with a Betacounter
Trilux (Perkin Elmer, Waltham, MA, USA).
Data
HPLC Data acquisition used Empower 3 chromatography
data software (Waters, Eschborn, Germany). Values of
one-point measurements were calculated relative to
specific binding. Concentration–response competition
binding data were analyzed with Prism 6 (GraphPad
Table 1 Composition of plant extracts tested at the hH4R
Plant Part of the plant Abbreviation
Crocus sativus Flower (A)
Cuminum cyminum Seed (B)
Nigella sativa Seed (C)
Thymus serpyllum Leaf (D)
Cuminum karamani Seed (E)
Ephedra foeminea Stem (F)
Curcuma longa Rhizome Crude extract
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Software Inc., San Diego, CA, USA). The Ki values were
calculated from the IC50 values using the Cheng–Prusoff
equation [18]. Values of binding data obtained are means
of three experiments, each performed as triplicates.
Values of binding data obtained by eleven and ten point
measurements are means of three independent experi-
ments run in at least duplicates. Binding data is given as
95% confidence intervals and are complemented by
means for six, eight, ten and eleven point measurements.
One-point measurements are reported as means with the
respective ranges.
Results
The methanolic extracts ofC. longa,Crocus sativus,Nigella
sativa, Thymus serpyllum, Cuminum karamani (Carvon
coptikum), Cuminum cyminum and Ephedra foeminea
(Table 1) were tested for their inhibition of radioligand
binding at the hH4R from purified membrane preparations.
The plant extracts displayed poor activity at the receptor
(\50% inhibition at 5 lg/mL), with the exception of the
methanolic extract of C. longa that showed strong activity
(complete inhibition at 10 lg/mL) (Table 2). As extracts
(A)–(F) showed low affinities, their further evaluation was
discontinued after two independent experiments in this
rough pre-screening.
Due to its superior affinity the methanolic curcuma
extract was further purified, which resulted in three
chemically defined compounds (1–3). Curcumin (1),
demethoxycurcumin (2), and bis-(4-hydroxy-cin-
namoyl)methane (3), 1,7-bis(4-hydroxyphenyl)hepta-1,6-
diene-3,5-dione) (Fig. 1) were collected using a preparative
HPLC, eluting at 10.20 (1), 9.66 (2) and 9.20 min (3),
respectively (purity[90%), and showing UV–Vis spectra
with kmax at 425 nm (1), 421 nm (2) and 416 nm (3).
The compounds and the crude extract were able to
inhibit radioligand binding at the hH4R by more than 70%
in measurements at 10 lg/mL. Compound (1) showed
highest inhibition of the three isolated compounds with
89% (1)[77% (2)[71% (3) inhibition, while the strongest
activity was shown for the crude extract with a complete
inhibition of radioligand binding (adjusted p value\0.05)
(Fig. 2; Table 2). Statistical analysis showed, that the
comparison of the crude extracts activity against the three
compounds (1)–(3) was significant (adjusted p values
\0.05), activity comparison of compound (1) against (2)
was significant (adjusted p value = 0.03) and comparisons
of activities from compound (1) against (3) and compound
(3) against (2) were not significant.
The tested compounds and the crude extract showed
clear concentration–response effects in radioligand binding
studies. Competition binding assays resulted in 95% con-
fidence intervals for the estimated Ki values ranging
Fig. 1 Chemical structures of the fractionated compounds, curcumin, demethoxycurcumin, and bis-(4-hydroxy-cinnamoyl)methane
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between 1.57–2.31 lg/mL (1), 2.26–3.04 lg/mL (2) and
3.16–4.49 lg/mL (3). This led to molar values of
4.26–6.26 lM (1), 6.66–8.97 lM (2) and 10.24–14.57 lM
(3), respectively (Table 3), for the purified compounds.
Highest activity was shown for the crude extract with an
estimated 95% confidence interval for the Ki value span-
ning 0.50–0.81 lg/mL, indicating a synergistic effect of all
compounds.
It is noteworthy that the crude extract as well as the
isolated curcumin (1) showed stronger binding to the hH4R
than pure curcumin with a Ki value of 5.54 lM [95% CI
(4.47–6.86 lM)] or 2.04 lg/mL [95% CI (1.65–2.53 lg/
mL)]. For verification, the evaluation was repeated with a
second extract preparation from Curcuma longa. It dis-
played a Ki value of 9.36 lg/mL [95% CI (4.96–17.68 lg/
mL)], while a second batch of pure curcumin (curcumin 2)
confirmed the first measurement with a measured Ki value
of 4.97 lM [95% CI (3.26–7.57 lM)] or 1.83 lg/mL [95%
CI (1.20–2.79 lg/mL)] (Fig. 3; Table 3).
Discussion
The study showed a superiority of C. longa crude extract
and isolated curcumin in contrast to pure curcumin. This
could be due to the presence of glycosides, complex car-
bohydrates or associated plant compounds like other
polyphenols, that are not detectable in the used detector
system, but are known for inheriting anti-inflammatory
effects [19]. Although not yet tested at the hH4R, their
attendance could result in synergistic effects in the in vitro
testing-systems. The superiority of extracts in comparison
to purified compounds is well reported [20] and could be
one reason why clinical studies that used pure curcumin
instead of extracts cannot confirm the in vitro activity often
reported. The discrepancy in activity between different
batches of the same extract may be caused by the natural
deviation of compound composition in plants. The com-
pounds concentration and composition strongly depends on
the environmental conditions, gathering seasons and
extraction conditions. Though a thorough standardization
method is essential for the therapies success when using
plant extracts. Although JNJ-7777120, a well-studied ref-
erence hH4R antagonist, displays a Ki value of 22.26 nM,
compounds showing activity in low micromolar concen-
trations could serve as potential lead structures for
designing optimized and structurally novel hH4R ligands
[21]. Achievable plasma concentrations of curcumin in
in vivo testings are in the same range as affinities in our
in vitro H4 studies of curcumins methanolic extracts and
isolated compounds. Thus, an interaction with the H4
receptor has to be considered when assessing anti-inflam-
matory effects of curcumin and its extracts. In humans
peak plasma levels of curcumin after the oral dosing of 8 g
were 1.77 lM [22]. The simultaneous application of piper
alkaloids (2 g/kg curcumin ? 20 mg/kg alkaloids) resulted
in maximal serum concentrations of 0.18 lg/mL [23] and
special formulations like nanocurcumin [24] or poly lactic-
co-glycolic acid encapsulated curcumin [25] are on the rise
to improve its bioavailability. Complex carbohydrates that
are attendant in most extracts could further enhance
bioavailability of the extracts [26]. At the same time cur-
cumin displays very low toxicity even at high doses up to
12 g per day [22] allowing application of reasonable
therapeutic doses in anti-inflammatory treatment. Although
curcumin has traditionally been used against inflammatory
diseases and in vitro as well as in vivo data supports the
anti-inflammatory effects, the clinical effectiveness as well
as the main molecular target still needs to be proven. This
led to a wide discussion whether or not the pharmacolog-
ical use of curcumin and its derivatives should be
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Fig. 2 Percentual inhibition of radioligand binding at hH4R of
curcumas extract and fractions (1)–(3) (10 lg/mL) n = 3 independent
experiments each performed in triplicates. Data are given as mean
with the respective ranges
Table 3 Estimated 95% CI and Ki values of curcumas crude extract, the compounds (1)–(3) and pure curcumin
Crude extract Crude extract 2 Curcumin Curcumin 2 Compound (1) Compound (2) Compound (3)
Ki
(95% CI) lg/mL
–
(0.50–0.81)
9.36
(4.96–17.68)
2.04
(1.65–2.53)
1.83
(1.20–2.79)
1.90
(1.57–2.31)
–
(2.26–3.04)
–
(3.16–4.49)
MW g/mol – – 368.39 368.39 368.39 338.36 308.33
Ki
(95% CI) lM
– – 5.54
(4.47–6.86)
4.97
(3.26–7.57)
5.17
(4.26–6.26)
–
(6.66–8.97)
–
(10.24–14.57)
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recommended and how in vitro investigations may be
interpreted [27]. Certainly pure curcumin will not be the
miracle cure of inflammations, but considering the com-
prehensive scientific data of its activity against
inflammatory targets [15] the adjuvant treatment of
inflammation with curcumin can be considered. Thereby,
the bioavailability of a given formulation, the composition
of bioactive compounds in an extract or capsule and a
potential affinity optimization of the lead-compounds could
be taken into account.
In conclusion, our research reveals that among other
inactive plant extracts, C. longa and three of its isolated
compounds display affinity at the hH4R, despite not
showing typical structure motifs [28]. They are not posi-
tively charged at physiological pH value and do not contain
the aminergic structure of typical imidazole or non-imi-
dazole hH4R ligands. Thus, dicinnamoyl methanes might
depict reasonable lead structures for novel scaffolds in
hH4R targeting. Further evaluation of different derivatives
will be necessary to allow a thorough structure–activity
relationship evaluation, as there are only minor structure
differences between the three compounds.
Although the hH4R plays an important role in chemotaxis,
inflammation and autoimmune disorders, at recent date there
are no approved drugs on the market, leaving the develop-
ment of new ligands at this receptor highly desired.We found
that the crude extract of C. longa displays higher potency
than its purified compounds. This illustrates the advantages
of using complex extracts in pharmaceutical therapy as they
sometimes surpass their isolated compounds in therapeutic
potency due to synergistic effects [29]. When using extracts
in pharmacotherapy it is important to take care of the natu-
rally deviating compound concentrations in plants and a
thorough standardizationmethod of extracts is essential for a
phytotherapy’s success. The conclusive data of in vitro as
well as in vivo results of pharmacologic investigations can
support the use of C. longa, especially extracts, in the adju-
vant treatment of inflammatory diseases when combined
with modern, orthodox medicine.
Within this study, we were able to evaluate seven dif-
ferent natural extracts at the hH4R and identified curcumin
derivatives as potential lead for future drug development.
Thereby, we further characterized curcumins mode of
action on molecular targets in fighting inflammatory events
and extended the lead structure database of biologically
active compounds at the hH4R.
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Fig. 3 Concentration–response
curves for the crude extract 2,
compound (1), curcumin and
curcumin 2. Data are given as
mean with the respective 95%
CI. All assays were performed
in three experiments, each run at
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